PD: Pramipexole (AAN report)

Subject: PD: Pramipexole (AAN report)

Date: 4/26/1999

1. Long-term safety and efficacy of pramipexole in early Parkinson's disease
SB Bressman, LM Shulman, CM Tanner, AH Rajput, KM Shannon, E Wright
Neurology 1999;52(Suppl 2):A261

Pramipexole is effective as monotherapy in early PD, according to this open-label extension of a previously reported double-blind trial. More than half of the 282 patients originally enrolled remained on pramipexole as the sole dopaminergic therapy at a mean dose of 4 mg/day, after three years of treatment. Approximately 60% of patients were on selegiline, as well. Principal adverse events were somnolence, dizziness, nausea, insomnia, and constipation.

Supported by Pharmacia & Upjohn

2. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease
WJ Weiner, SA Factor, J Jankovic, RA Hauser, JW Tetrud, CH Waters, LM Shulman, PM Glassman, B Beck, D Paume, C Doyle, and the Pramipexole Study Group
Neurology 1999;52(Suppl 2):A261-262

3. Four year safety and adverse events in an open-label experience of 306 patients on pramipexole for Parkinson's disease
SA Factor, WJ Weiner, J Jankovic, RA Hauser, JW Tetrud, CH Waters, LM Shulman, PM Glassman, B Beck, D Paume, C Doyle, and the Pramipexole Study Group
Neurology 1999;52(Suppl 2):A407-408

Pramipexole is effective as adjunctive therapy in advanced PD, according to this open-label extension of a previously reported double-blind trial. Scores on UPDRS II an III remained stable for 2-3 years, followed by gradual return to baseline. Treatment complications and tremor scores while "on" remained above baseline for the entire study. Principal adverse events were dyskinesias, asymptomatic orthostatic hypotension, and dizziness, with a decrease of incidence after the first six months.

Supported by Boehringer Ingelheim Pharmaceuticals

E-MOVE Editor: Richard Robinson, NASW, WE MOVE

Related CME Activities - Valid for AMA PRA Category 1 Credits(s)™